Merck & Co Inc and AstraZeneca PLC - Pharmaceutical companies based in Rahway, New Jersey and Cambridge, England, respectively - Phase 3 Komet trial shows statistically significant and clinically meaningful improvement in objective response rate in adult neurofibromatosis patients treated with AstraZeneca and Merck’s joint-developed medication Koselugo. The condition is a rare progressive genetic disease in which tumours develop on nerve sheaths and may lead to disfigurement, motor dysfunction, pain, airway dysfunction, visual impairment and bladder or bowel dysfunction. Koselugo is approved to treat children with the disease but there is little intervention available for adults.
‘Adults with NF1 are in critical need of treatment options to help manage symptomatic, inoperable plexiform neurofibromas. These positive results from the Phase 3 Komet trial demonstrate the potential to expand the use of Koselugo beyond pediatric patients to also treat adult patients living with this rare and challenging genetic condition,’ says Scot Ebbinghaus, vice president, global clinical development, Merck Research Laboratories.
Merck current share price: $99.44
12-month change: down 3.0%
AstraZeneca current share price 9,860.79 pence
12-month change: down 3.8%
Copyright 2024 Alliance News Ltd. All Rights Reserved.
